George S.N. Hui, Ph.D.
Director, Molecular and Cellular Immunology Core Professor Department of Tropical Medicine, Medical Microbiology and Pharmacology John A. Burns School of Medicine
Phone: 808-692-1609
Office: BSB 320K
Email: ghui [at] hawaii.edu
Curriculum Vitae
Bio
Academic Positions:
|
|
1987 - 1991 |
Assistant Research Professor, Department of Tropical Medicine, University of Hawaii |
1991 - 1996 |
Associate Research Professor, Department of Tropical Medicine, University of Hawaii |
1995 - 1996 |
NIH-TMRC Visiting Scientist, Research Institutes for Tropical Medicine, Philippines |
1996 - present |
Research Professor (with tenure), Department of Tropical Medicine, University of Hawaii |
Other Research-Related Positions/Memberships:
|
|
1991 - 2000 |
American Society of Tropical Medicine & Hygiene, member |
1994 - 1996 |
American Society of Tropical Medicine & Hygiene, Scientific Program Committee |
1994 - 1996 |
Chairperson, University of Hawaii, System-wide Animal Care and Use Committee |
1998 |
Ad hoc Consultant, Trop.Diseases Res. (TDR), WHO, Vaccine Discovery Research |
1997 - 1999 |
University of Hawaii Committee on Human Subjects (IRB) |
1999 |
External grant review consultant for the Austrian Science Fund |
1999 - present |
Consultant, Hawaii Biotechnology Inc. |
2005 - present |
Consultant, Neugenesis Inc. |
2008 |
President. American Society for Microbiology, Hawai`i Branch |
2009-present |
External consultant for AIBS, Military Malaria Vaccine Program |
NIH Study Sections:
|
|
1999 |
NIAID/NIH, Tropical Medicine & Parasitology (TMP) Special Study Section for RFA |
1997, 2000, 02-03 |
NIAID/NIH, Vaccine Study Section (VAC 01, VAC 04, VAC 10) |
2003 |
NIAID/NIH, SEP, Member of parent panel, and Sub-committee Chair, Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases (RCE) |
2004 |
NIAID, SEP, Operation of a Facility for Testing of Malaria Vaccines in Adult Human Subjects |
2006 |
CSR/NIH, ZRG1 IMM-K (13) B, Influenza Vaccine Development |
2006 |
NIAID/NIH, ZAI1-MH-M-C2. Malaria Vaccine Production and Support Services |
2004 - 2009 |
CSR/NIH, Vaccines for Microbial Diseases (VMD) |
2010 |
NIAID/NIH, ZAI1 AWA-M, M2. SEP. International Center of Excellence for Malaria Research |
|
CSR/NIH, ZRG1 IMM-G 12B Small Business Grant Microbial Vaccine Development |
2010 - 2011 |
CSR/NIH, ZRG1 ZRG1 IMM-F07-C(20)L B cell Regulation & Tolerance to Cancer Antigens |
2011 |
CSR/NIH, Bioengineering & Biosciences IRG, Biomaterials and Biointerfaces |
|
CSR/NIH, ZRG1 IMM-K(02)M, Immunology |
Research Keywords: Malaria, vaccine, adjuvant
Research Overview
My research is on the development of blood stage malaria vaccines; and studies on the use of different vaccine adjuvants for the malaria vaccines. Specifically, we focus on the design of vaccines based on the Merozoite Surface Protein 1 (MSP1) by defining critical T and B epitopes of the molecule. We also evaluate the use of a variety of immunological adjuvants to enhance vaccine potency and at the same time define the critical pathway for adjuvants’ mode of action. Our approaches also study the use of nanoparticle platforms for antigen delivery. Beside research, I am also the director of a biomedical sciences research training program for high school and college bound students called the STEP-UP Program (http://stepup.niddk.nih.gov) that is supported by NIDDK/NIH. The project recruits minority and disadvantage students from the Pacific Regions, Alaska and Puerto Rico into university/college research laboratories to engage in health related research under the mentorships of university faculty.
Selected Publications
-
Yanagihara R, Nerurkar VR, Hui G, Jacobs GA.
Pacific Center for Emerging Infectious Diseases Research.
Hawaii Journal of Medicine and Public Health
2017
more details...
-
Pusic K, Aguilar Z, McLoughlin J, Kobuch S, Xu H, Tsang M, Wang A, Hui G.
Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine.
FASEB Journal
2013
more details...
-
Pusic K, Clements D, Kobuch S, Hui G.
Antibody and T cell responses in reciprocal prime-boost studies with full-length and truncated merozoite surface protein 1-42 vaccines.
PLoS One
2013
more details...
-
Hui GS, Pusic KM.
Training the next generation of minority health scientists: a STEP-UP in the right direction.
Hawaii Medical Journal
2011
more details...
-
Pusic K, Xu H, Stridiron A, Aguilar Z, Wang A, Hui G.
Blood stage merozoite surface protein conjugated to nanoparticles induce potent parasite inhibitory antibodies.
Vaccine
2011
more details...
-
Pusic KM, Hashimoto CN, Lehrer A, Aniya C, Clements DE, Hui GS.
T-cell epitope regions of the P. falciparum MSP1-33 critically influence immune responses and in vitro efficacy of MSP1-42 vaccines.
PLoS One
2011
more details...
-
Hui G, Choe D, Hashimoto C.
Biological activities of anti-merozoite surface protein-1 antibodies induced by adjuvant-assisted immunizations in mice with different immune gene knockouts.
Clinical and Vaccine Immunology
2008
more details...
-
Hui GS, Hashimoto CN.
Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment.
International Immunopharmacology
2008
more details...
-
Hui G, Hashimoto C.
The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine
Vaccine
2007
more details...
-
Hui G, Hashimoto C.
Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.
Vaccine
2007
more details...
-
Hui G, Hashimoto C.
Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes.
Vaccine
2007
more details...
-
Nagata M, Wong T, Clements D, Hui G.
Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies.
Experimental Parasitology
2007
more details...
-
Yuen D, Leung WH, Cheung R, Hashimoto C, Ng SF, Ho W, Hui G.
Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development.
Vaccine
2007
more details...
Grants
-
Grant No / Title: 2R25DK078386-11 / Pacific High Schools STEP-UP to Biomedical Research
Status / Agency: Awarded / NIH/NIDDK
Start Date / End Date: 01 March 2017 / 28 February 2022
-
Grant No / Title: R25DK078386 / Pacific High Schools STEP-UP to Biomedical Research
Status / Agency: Awarded / NIH/NIDDK
Start Date / End Date: 01 April 2012 / 31 March 2017
|